We are a clinical stage biopharmaceutical company dedicated

to develop drugs for neurological disorders



Our vocation is to develop first-in-class innovative drugs to treat patients with traumatic or severe neurological disorders with high unmet medical needs.

Our ambition is to improve the recovery of the functionality and the quality of life of patients.




Our products are First-in-Class drug candidates covering a large set of indications in neural-repair treatment (traumatic and degenerative diseases) with high unmet medical needs.


  • NX210, our lead product, is an injectable drug. A Phase I Tolerance clinical trial is planned in patients with Spinal Cord Injury.


  • Strong rationale and promising preliminary results in neurodegenerative diseases.